Review



yellow fever virus yfv synthetic rna  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    ATCC yellow fever virus yfv synthetic rna
    Yellow Fever Virus Yfv Synthetic Rna, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 88 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/yellow+fever+virus+yfv+synthetic+rna/Yellow+fever+virus/pmc12896270-143-64-76
    Average 93 stars, based on 88 article reviews
    yellow fever virus yfv synthetic rna - by Bioz Stars, 2026-10
    93/100 stars

    Images

    Related Articles

    Virus:

    Article Title: Performance evaluation of TaqMan Array Card real-time PCR for multi-pathogen detection in acute undifferentiated febrile illness
    Article Snippet: .. Cross reactivity was performed in duplicate using pathogens that were not included in the TAC, including Herpes simplex virus type 1 (HSV-1) strain KOS (ATCC; VR-1493), Varicella zoster virus (VZV) strain Ellen (ATCC; VR-1367), Influenza A virus strain A/PR/8/34 (ATCC; VR-95), Influenza B virus strain B/Lee/40 (ATCC; VR-1535), Respiratory syncytial virus (RSV) strain A-2 (ATCC; VR-1540), Hepatitis E virus (HEV) synthetic RNA (ATCC; VR-3258SD), Yellow fever virus (YFV) synthetic RNA (Amplirun ® ; MBC100-R), Enterococcus faecalis (ATCC; 29212), Streptococcus pyogenes (BCID_125: SAMN53398568), Streptococcus dysgalactiae (BCID_24: SAMN53401927), Streptococcus pasteurianus (BCID_69: SAMN53398566), Staphylococcus hominis (BCID_85: SAMN53398565), Staphylococcus epidermidis (BCID_117: SAMN53398567), Pseudomonas aeruginosa (ATCC; 27853), Acinetobacter baumannii (SI-baum0423: SAMN51289989), Burkholderia cepacian (BCID_94: SAMN53401926), Enterobacter hormaechei (BCID_54: SAMN53398569), and Proteus mirabilis (BCID_62: SAMN53398570). ..



    Similar Products

    yellow fever virus yfv synthetic rna  (ATCC)
    93
    ATCC yellow fever virus yfv synthetic rna
    Yellow Fever Virus Yfv Synthetic Rna, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/yellow+fever+virus+yfv+synthetic+rna/Yellow+fever+virus/pmc12896270-143-64-76
    Average 93 stars, based on 1 article reviews
    yellow fever virus yfv synthetic rna - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    yellow 193 fever virus yfv synthetic rna  (ATCC)
    99
    ATCC yellow 193 fever virus yfv synthetic rna
    Yellow 193 Fever Virus Yfv Synthetic Rna, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/yellow+fever+virus+yfv+synthetic+rna/Enterococcus+faecalis+(Andrewes+and+Horder)+Schleifer+and+Kilpper-Balz/pm41618190-74-79-91
    Average 99 stars, based on 1 article reviews
    yellow 193 fever virus yfv synthetic rna - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    yfv synthetic rna standard  (ATCC)
    94
    ATCC yfv synthetic rna standard
    Figure 2. Complement-mediated virolysis with ZIKV-cross-reactive antibodies is strongly associated with protection from subsequent DHF/ DSS and symptomatic DENV infection (A–D) Pre-infection plasma samples prior to DF (green; n = 31) versus DHF/DSS (gold; n = 33) were incubated with mature DENV2, mature DENV3, ZIKV, and <t>YFV</t> virions. (A and B) Left: 1:10 dilution of plasma; right: 1:30 dilution of plasma. (E) Pre-inapparent (blue circles; n = 30) and pre-symptomatic (orange circles; n = 29) secondary DENV3 infection plasma samples were incubated with ZIKV virions. After incubating virions with plasma samples in the presence of guinea pig complement at 37◦C followed by one freeze-thaw cycle, viral <t>RNA</t> of unstable virions were digested with RNase A, while intact RNA was extracted from virolysis-resistant virions. Dengue-naive plasma samples were used as negative controls and set to the maximum amount of detectable RNA (lack of virolysis) in the assay. Virion lysis was quantified by measuring viral RNA via RT-qPCR (to measure the number of genome copies) and calculated as the percentage (%) of virion lysis as described in the STAR Methods. Shown are the median per centage of virolysis (middle line), 25th to 75th percentile (box), and 5th to 95th percentile (whiskers), as well as the raw data (points). Asterisks indicate Benjamini- Hochberg-adjusted p values for Mann-Whitney U tests, with false discovery rate (FDR) correction applied (****p < 0.0001, and ns, non-significant).
    Yfv Synthetic Rna Standard, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/yellow+fever+virus+yfv+synthetic+rna/Quantitative+Synthetic+RNA+from+Yellow+fever+virus/pm40333188-230-26-30
    Average 94 stars, based on 1 article reviews
    yfv synthetic rna standard - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    synthetic rna  (ATCC)
    94
    ATCC synthetic rna
    Figure 2. Complement-mediated virolysis with ZIKV-cross-reactive antibodies is strongly associated with protection from subsequent DHF/ DSS and symptomatic DENV infection (A–D) Pre-infection plasma samples prior to DF (green; n = 31) versus DHF/DSS (gold; n = 33) were incubated with mature DENV2, mature DENV3, ZIKV, and <t>YFV</t> virions. (A and B) Left: 1:10 dilution of plasma; right: 1:30 dilution of plasma. (E) Pre-inapparent (blue circles; n = 30) and pre-symptomatic (orange circles; n = 29) secondary DENV3 infection plasma samples were incubated with ZIKV virions. After incubating virions with plasma samples in the presence of guinea pig complement at 37◦C followed by one freeze-thaw cycle, viral <t>RNA</t> of unstable virions were digested with RNase A, while intact RNA was extracted from virolysis-resistant virions. Dengue-naive plasma samples were used as negative controls and set to the maximum amount of detectable RNA (lack of virolysis) in the assay. Virion lysis was quantified by measuring viral RNA via RT-qPCR (to measure the number of genome copies) and calculated as the percentage (%) of virion lysis as described in the STAR Methods. Shown are the median per centage of virolysis (middle line), 25th to 75th percentile (box), and 5th to 95th percentile (whiskers), as well as the raw data (points). Asterisks indicate Benjamini- Hochberg-adjusted p values for Mann-Whitney U tests, with false discovery rate (FDR) correction applied (****p < 0.0001, and ns, non-significant).
    Synthetic Rna, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/yellow+fever+virus+yfv+synthetic+rna/Quantitative+Synthetic+RNA+from+Yellow+fever+virus/pm35130561-173-14-17
    Average 94 stars, based on 1 article reviews
    synthetic rna - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 2. Complement-mediated virolysis with ZIKV-cross-reactive antibodies is strongly associated with protection from subsequent DHF/ DSS and symptomatic DENV infection (A–D) Pre-infection plasma samples prior to DF (green; n = 31) versus DHF/DSS (gold; n = 33) were incubated with mature DENV2, mature DENV3, ZIKV, and YFV virions. (A and B) Left: 1:10 dilution of plasma; right: 1:30 dilution of plasma. (E) Pre-inapparent (blue circles; n = 30) and pre-symptomatic (orange circles; n = 29) secondary DENV3 infection plasma samples were incubated with ZIKV virions. After incubating virions with plasma samples in the presence of guinea pig complement at 37◦C followed by one freeze-thaw cycle, viral RNA of unstable virions were digested with RNase A, while intact RNA was extracted from virolysis-resistant virions. Dengue-naive plasma samples were used as negative controls and set to the maximum amount of detectable RNA (lack of virolysis) in the assay. Virion lysis was quantified by measuring viral RNA via RT-qPCR (to measure the number of genome copies) and calculated as the percentage (%) of virion lysis as described in the STAR Methods. Shown are the median per centage of virolysis (middle line), 25th to 75th percentile (box), and 5th to 95th percentile (whiskers), as well as the raw data (points). Asterisks indicate Benjamini- Hochberg-adjusted p values for Mann-Whitney U tests, with false discovery rate (FDR) correction applied (****p < 0.0001, and ns, non-significant).

    Journal: Cell reports

    Article Title: Anti-dengue virus antibodies that elicit complement-mediated lysis of Zika virion correlate with protection from severe dengue disease.

    doi: 10.1016/j.celrep.2025.115613

    Figure Lengend Snippet: Figure 2. Complement-mediated virolysis with ZIKV-cross-reactive antibodies is strongly associated with protection from subsequent DHF/ DSS and symptomatic DENV infection (A–D) Pre-infection plasma samples prior to DF (green; n = 31) versus DHF/DSS (gold; n = 33) were incubated with mature DENV2, mature DENV3, ZIKV, and YFV virions. (A and B) Left: 1:10 dilution of plasma; right: 1:30 dilution of plasma. (E) Pre-inapparent (blue circles; n = 30) and pre-symptomatic (orange circles; n = 29) secondary DENV3 infection plasma samples were incubated with ZIKV virions. After incubating virions with plasma samples in the presence of guinea pig complement at 37◦C followed by one freeze-thaw cycle, viral RNA of unstable virions were digested with RNase A, while intact RNA was extracted from virolysis-resistant virions. Dengue-naive plasma samples were used as negative controls and set to the maximum amount of detectable RNA (lack of virolysis) in the assay. Virion lysis was quantified by measuring viral RNA via RT-qPCR (to measure the number of genome copies) and calculated as the percentage (%) of virion lysis as described in the STAR Methods. Shown are the median per centage of virolysis (middle line), 25th to 75th percentile (box), and 5th to 95th percentile (whiskers), as well as the raw data (points). Asterisks indicate Benjamini- Hochberg-adjusted p values for Mann-Whitney U tests, with false discovery rate (FDR) correction applied (****p < 0.0001, and ns, non-significant).

    Article Snippet: Standard curves were prepared using seven 10-fold dilutions of a DENV2 8891 synthetic fragment, DENV3 UNC3009 in vitro transcribed RNA, ZIKV RNA standard (ATCC VR3252SD) or YFV synthetic RNA standard (ATCC VR-3253SD).

    Techniques: Infection, Clinical Proteomics, Incubation, Lysis, Quantitative RT-PCR, MANN-WHITNEY